Triple Therapy with Ecabet Sodium, Amoxicillin and Lansoprazole for 2 Weeks as the Rescue Regimen for H. pylori Infection

Access this Article

Search this Article



<b>Background/Aim</b> Ecabet sodium has an anti-<i>H. pylori</i> effect. We assessed the efficacy of ecabet sodium in the rescue therapy for the eradication of <i>H. pylori</i>.<br> <b>Methods</b> A total of 74 patients with failed eradication of <i>H. pylori</i> after triple therapy with lansoprazole 30 mg bid, amoxicillin 750 mg bid and clarithromycin 200 mg bid were enrolled. They were randomly assigned to the three treatment groups as follows: LAC, lansoprazole 30 mg + amoxicillin 750 mg + clarithromycin 200 mg bid for 1 week; LAC2E, lansoprazole 30 mg bid + amoxicillin 750 mg bid + clarithromycin 200 mg bid + ecabet sodium 2 g bid for 1 week; and LA2E, lansoprazole 30 mg bid + amoxicillin 750 mg bid + ecabet sodium 2 g bid for 2 weeks. Eradication of <i>H. pylori</i> was assessed by the 13C-urea breath test after treatment.<br> <b>Results</b> Eradication rates in intention-to-treat and per-protocol analyses were 20.0% (95% CI: 6.8-40.7) and 20.0% (6.8-40.7) with LAC, respectively, and 16.0% (4.5-36.1) and 17.4% (5.0-38.8) with LAC2E. In contrast, respective rates with LA2E were 75% (53.3-90.2) and 85.7% (63.7-97.0), which were significantly higher than those with LAC (p<0.001 for both ITT and PP) and LAC2E (p<0.001 for both ITT and PP).<br> <b>Conclusion</b> Triple therapy with ecabet sodium, lansoprazole and amoxicillin for 2 weeks was effective as the rescue therapy after failure of the standard clarithromycin-based regimen.<br>


  • Internal Medicine

    Internal Medicine 50(5), 369-374, 2011

    The Japanese Society of Internal Medicine


Page Top